Related Experiment Videos
[New developments in chemotherapy for metastasized bladder cancer]
1Academisch Ziekenhuis, afd. Interne Oncologie, Postbus 5201, 3008 AE Rotterdam. wit@onch.azr.nl
Nederlands Tijdschrift Voor Geneeskunde
|January 5, 2002
Summary
Methotrexate vinblastine doxorubicin cisplatin (MVAC) is a standard for metastatic bladder cancer. Cisplatin and gemcitabine (GC) offer similar efficacy with reduced toxicity, with ongoing research into adding paclitaxel or using carboplatin-based regimens for less fit patients.
Area of Science:
- Oncology
- Medical Chemistry
- Clinical Pharmacology
Context:
- Metastatic bladder cancer treatment historically relies on Methotrexate vinblastine doxorubicin cisplatin (MVAC).
- This regimen is indicated for fit patients (WHO performance status 0-1) with adequate renal function.
- MVAC achieves response rates of 40-57% and median survival of approximately 15 months.
Purpose:
- To evaluate alternative chemotherapy regimens for metastatic bladder cancer.
- To compare the efficacy and toxicity profiles of different treatment combinations.
- To identify optimal treatment strategies for both fit and less fit patient populations.
Summary:
- Cisplatin and gemcitabine (GC) combination chemotherapy presents a viable alternative to MVAC.
- GC demonstrates comparable effectiveness to MVAC but with significantly lower toxicity.
- Ongoing studies are investigating the addition of paclitaxel to GC and carboplatin-based regimens for palliative care in less fit patients.
Impact:
- GC offers a potentially safer and equally effective treatment option for metastatic bladder cancer.
- Investigational regimens aim to broaden treatment accessibility and improve outcomes for diverse patient groups.
- This research contributes to refining chemotherapy protocols for bladder cancer, balancing efficacy with patient tolerance.